<?xml version="1.0" encoding="UTF-8"?>
<article article-type="research-article" dtd-version="1.3" xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>Czech and Slovak Ophthalmology</journal-title>
      </journal-title-group>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">338</article-id>
      <article-id pub-id-type="doi">10.31348/2024/36</article-id>
      <article-categories>
        <subj-group>
          <subject>Original article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Screening and Treatment of Retinopathy of Prematurity at The Department of Pediatric Ophthalmology at The Faculty of Medicine, Masaryk University and University Hospital Brno</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Rozsypalová</surname>
            <given-names>Marie</given-names>
          </name>
          <contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-8082-0116</contrib-id>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Autrata</surname>
            <given-names>Rudolf</given-names>
          </name>
          <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2689-882X</contrib-id>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Šenková</surname>
            <given-names>Kateřina</given-names>
          </name>
          <contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-7388-4390</contrib-id>
        </contrib>
      </contrib-group>
      <pub-date date-type="pub" publication-format="electronic">
        <day>27</day>
        <month>8</month>
        <year>2024</year>
      </pub-date>
      <issue>6</issue>
      <elocation-id>3</elocation-id>
      <abstract>
        <p>Aim: Evaluation of screening and treatment of retinopathy of prematurity (ROP) at the Department of Pediatric Ophthalmology. Material and Methods: Retrospective evaluation of the medical records of premature babies, born in the period 2012–2022 and treated at the Neonatology Department and the Neonatology ICU at the University Hospital Brno. On average 150 children annually are put forward for screening of ROP. A total of 1694 premature infants were examined during the 11-year monitored period. Results: There were 100 patients who reached the stage of ROP requiring treatment, and the results showed that the most endangered group were those with a birth weight below 1000 g. The gestational age at the start of therapy was also assessed. Treatment of ROP was most often carried out by means of a combination of laser photocoagulation of the retina and intravitreal application of anti-VEGF (35 patients), as well as monotherapies: application of anti-VEGF (30 patients), laser photocoagulation of the retina (28 patients) and cryotherapy (2 patients in total). None of the patients reached ROP stage 4 or 5. The number of patients in need of treatment in the past three years has decreased significantly. Conclusion: The article documents the screening and trend in the treatment of retinopathy of premature infants in recent years. Of interest here are the changes in the incidence of ROP from 2020, which reflect the positive development of neonatological care.Retinopathy of prematurity is still a disease that can lead to blindness of premature infants, but early screening and treatment can prevent this. Progress in the care of newborns born prematurely is also positively reflected in the incidence of this serious disease.</p>
      </abstract>
      <kwd-group>
        <kwd>retinopathy of prematurity</kwd>
        <kwd>update of the international classification</kwd>
        <kwd>screening</kwd>
        <kwd>treatment</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="R2773">
        <mixed-citation>Daruich A, Bremond-Gignac D, Behar-Cohen F, Kermorvant E. Rétinopathie du prématuré: de la prévention au traitement [Retinopathy of prematurity: from prevention to treatment]. Med Sci (Paris). 2020 Oct;36(10):900-907. French. doi: 10.1051/medsci/2020163<pub-id pub-id-type="doi">10.1051/medsci/2020163</pub-id></mixed-citation>
      </ref>
      <ref id="R2774">
        <mixed-citation>de las Rivas Ramírez N, Luque Aranda G, Rius Díaz F, et al. Risk factors associated with Retinopathy of Prematurity development and progression. Sci Rep. 2020;12:21977.</mixed-citation>
      </ref>
      <ref id="R2775">
        <mixed-citation>Hong EH, Shin YU, Cho H. Retinopathy of prematurity: a review of epidemiology and current treatment strategies. Clin Exp Pediatr. 2022 Mar;65(3):115-126. doi: 10.3345/cep.2021.00773<pub-id pub-id-type="doi">10.3345/cep.2021.00773</pub-id></mixed-citation>
      </ref>
      <ref id="R2776">
        <mixed-citation>Chiang MF, Quinn GE, Fielder AR, et al. International Classification of Retinopathy of Prematurity, Third Edition. Ophthalmology. 2021 Oct;128(10):e51-e68. doi: 10.1016/j. ophtha.2021.05.031<pub-id pub-id-type="doi">10.1016/j</pub-id></mixed-citation>
      </ref>
      <ref id="R2777">
        <mixed-citation>Wilkinson AR, Adams GGW, Fleck BW, Nieto-Hernandez R; Guideline Development Groups (GDG) of the Royal College of Paediatrics and Child Health (RCPCH) and the Royal College of Ophthalmologists (RCOphth). UK screening and treatment of retinopathy of prematurity Updated 2022 Guidelines. Early Hum Dev. 2023 Mar;177-178:105715. doi: 10.1016/j.earlhumdev.2023.105715<pub-id pub-id-type="doi">10.1016/j.earlhumdev.2023.105715</pub-id></mixed-citation>
      </ref>
      <ref id="R2778">
        <mixed-citation>Kanski’s Clinical Ophtalmology 2020; p.538.</mixed-citation>
      </ref>
      <ref id="R2779">
        <mixed-citation>Good WV; Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233-248; discussion 248-520.</mixed-citation>
      </ref>
      <ref id="R2780">
        <mixed-citation>Zobanová A, Brychcínová P, Autrata R, Šenková K. Screening, Treatment and Long-term Observation of Retinopathy of Prematurely Born Children in the Czech Republic. Cesk Slov Oftalmol. 2018;74(6):253-264.</mixed-citation>
      </ref>
      <ref id="R2781">
        <mixed-citation>Strube YNJ, Wright KW. Pathophysiology of retinopathy of prematurity. Saudi J Ophthalmol. 2022 Oct 14;36(3):239-242. doi: 10.4103/sjopt.sjopt_18_22<pub-id pub-id-type="doi">10.4103/sjopt.sjopt_18_22</pub-id></mixed-citation>
      </ref>
      <ref id="R2782">
        <mixed-citation>Wood EH, Chang EY, Beck K, et al. 80 Years of vision: preventing blindness from retinopathy of prematurity. J Perinatol. 2021 Jun;41(6):1216-1224. doi: 10.1038/s41372-021-01015-8<pub-id pub-id-type="doi">10.1038/s41372-021-01015-8</pub-id></mixed-citation>
      </ref>
      <ref id="R2783">
        <mixed-citation>Yucel OE, Eraydin B, Niyaz L, Terzi O. Incidence and risk factors for retinopathy of prematurity in premature, extremely low birth weight and extremely low gestational age infants. BMC Ophthalmol. 2022 Sep 13;22(1):367. doi: 10.1186/s12886-022-02591-9<pub-id pub-id-type="doi">10.1186/s12886-022-02591-9</pub-id></mixed-citation>
      </ref>
      <ref id="R2784">
        <mixed-citation>Dogra MR, Vinekar A. Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Treatment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income Countries. Pediatric Health Med Ther. 2023 Feb 15;14:59-69. doi: 10.2147/PHMT.S391591<pub-id pub-id-type="doi">10.2147/PHMT.S391591</pub-id></mixed-citation>
      </ref>
      <ref id="R2785">
        <mixed-citation>Enríquez AB, Avery RL, Baumal CR. Update on Anti-Vascular Endothelial Growth Factor Safety for Retinopathy of Prematurity. Asia Pac J Ophthalmol (Phila). 2020 Jul-Aug;9(4):358-368. doi: 10.1097/APO.0000000000000302<pub-id pub-id-type="doi">10.1097/APO.0000000000000302</pub-id></mixed-citation>
      </ref>
      <ref id="R2786">
        <mixed-citation>Sabri K, Ells AL, Lee EY, Dutta S, Vinekar A. Retinopathy of Prematurity: A Global Perspective and Recent Developments. Pediatrics. 2022 Sep 1;150(3):e2021053924. doi: 10.1542/peds.2021- 053924. PMID: 35948728<pub-id pub-id-type="doi">10.1542/peds.2021-</pub-id></mixed-citation>
      </ref>
      <ref id="R2787">
        <mixed-citation>Autrata R, Krejcírová I, Senková K, et al. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. E J Ophthalmol. 2012 Sep-Oct;22(5):687-694. doi: 10.5301/ejo.5000166<pub-id pub-id-type="doi">10.5301/ejo.5000166</pub-id></mixed-citation>
      </ref>
      <ref id="R2788">
        <mixed-citation>Fierson WM; American academy of pediatrics section on ophthalmology; american academy of ophthalmology; american association for pediatric ophthalmology and strabismus; american association of certified orthoptists. Screening Examination of Premature Infants for Retinopathy of Prematurity. Pediatrics. 2018 Dec;142(6): e20183061. doi: 10.1542/peds.2018-3061. Erratum in: Pediatrics. 2019 Mar;143(3)<pub-id pub-id-type="doi">10.1542/peds.2018-3061</pub-id></mixed-citation>
      </ref>
      <ref id="R2789">
        <mixed-citation>Hartnett ME. Retinopathy of Prematurity: Evolving Treatment With Anti-Vascular Endothelial Growth Factor. Am J Ophthalmol. 2020 Oct; 218:208-213. doi: 10.1016/j.ajo.2020.05.025, Erratum in: Am J Ophthalmol. 2021 Nov; 231:213<pub-id pub-id-type="doi">10.1016/j.ajo.2020.05.025</pub-id></mixed-citation>
      </ref>
      <ref id="R2790">
        <mixed-citation>Wang Z, Zhang Z, Wang Y, Di Y. Effect of ranibizumab on retinopathy of prematurity: A meta-analysis. Front Pharmacol. 2022 Aug 22; 13:897869. doi: 10.3389/fphar.2022.897869<pub-id pub-id-type="doi">10.3389/fphar.2022.897869</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
